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Abstract
We previously showed that increases in mean arterial pressure (MAP) follow-
ing administration of midodrine hydrochloride (MH) and nitro-L-arginine
methyl ester (L-NAME) resulted in increased mean cerebral blood flow veloc-
ity (MFV) during head-up tilt in hypotensive individuals with spinal cord
injury (SCI) and question if this same association was evident during cogni-
tive activation. Herein, we report MAP and MFV during two serial subtrac-
tion tasks (SSt) given before (predrug) and after (postdrug) administration of
MH; (10 mg), L-NAME (1 mg/kg) or no drug (ND) in 15 subjects with SCI
compared to nine able-bodied (AB) controls. Three-way factorial analysis of
variance (ANOVA) models were used to determine significant main and inter-
action effects for group (SCI, AB), visit (MH, L-NAME, ND), and time (pre-
drug, postdrug) for MAP and MFV during the two SSt. The three-way
interaction was significant for MAP (F = 4.262; P = 0.020); both MH
(30  26 mmHg; P < 0.05) and L-NAME (27  22 mmHg; P < 0.01) signifi-
cantly increased MAP in the SCI group, but not in the AB group. There was a
significant visit by time interaction for MFV suggesting an increase from pre-
drug to postdrug following L-NAME (6  8 cm/sec; P < 0.05) and MH
(4  7 cm/sec; P < 0.05), regardless of study group, with little change follow-
ing ND (3  3 cm/sec). The relationship between change in MAP and MFV
was significant in the SCI group following administration of MH (r2 = 0.38;
P < 0.05) and L-NAME (r2 = 0.32; P < 0.05). These antihypotensive agents,
at the doses tested, raised MAP, which was associated with an increase MFV
during cognitive activation in hypotensive subjects with SCI.
Introduction
Decentralized autonomic cardiovascular control in per-
sons with spinal cord injury (SCI) often results in chronic
hypotension and orthostatic hypotension (OH), particu-
larly in individuals with high cord lesions (i.e., above T6).
While most hypotensive individuals with chronic SCI
remain asymptomatic and do not complain of symptoms
associated with cerebral hypoperfusion (i.e., dizziness,
lightheadedness, blurry vision, nausea, etc.), evidence of
reduced resting cerebral blood flow (CBF) has been
reported in association with low systemic blood pressure
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(BP) in the SCI population (Yamamoto et al. 1980; Catz
et al. 2007; Wilson et al. 2010); although controversy
exists (Sahota et al. 2012; Phillips et al. 2014a). We
recently found that middle cerebral artery CBF velocity
(CBFv) was not increased during cognitive testing in indi-
viduals with SCI (Wecht et al. 2012), and noted signifi-
cantly impaired memory and marginally impaired
attention processing in hypotensive individuals with SCI
compared to a normotensive SCI cohort (Jegede et al.
2010). Given the potential adverse impact of asymp-
tomatic hypotension on CBF and cognitive function in
the SCI population treatment options for low BP should
be considered. However, we reported disparity between
the evidence of hypotension (40%) and the clinical
diagnosis (<1%) and treatment (<1%) in veterans with
SCI (Wecht et al. 2013b; Zhu et al. 2013), which we attri-
bute to the lack of evidence documenting the safe and
effective use of antihypotensive agents to raise BP and
improve CBF and cognitive performance in the SCI pop-
ulation.
In the United States, there are currently two FDA
approved medications available for treatment of symp-
tomatic neurogenic OH, an alpha-agonist, midodrine
hydrochloride (MH) and the norepinephrine precursor, L-
Threo-3,4-Dihydroxyphenylserine (droxidopa). We docu-
mented safe and effective increases in BP in hypotensive
individuals with SCI following a single dose of MH
(10 mg) (Wecht et al. 2010, 2011) and droxidopa
(400 mg) (Wecht et al. 2013a). In addition, we reported
that intravenous infusion of a nitric oxide synthase (NOS)
inhibitor, nitro-L-arginine methyl ester (L-NAME: 1.0 mg/
kg) increased supine and orthostatic BP (Wecht et al. 2008,
2009); however, L-NAME is an experimental antihypoten-
sive agent and does not have FDA approval. Importantly,
we noted a direct association between the orthostatic
change in BP and CBFv following administration of MH
and L-NAME in hypotensive individuals with SCI (Wecht
et al. 2010, 2011); however, we have not reported the
effects of these antihypotensive agents on BP and CBFv
during cognitive testing, and have not compared the BP
and CBFv responses to MH and L-NAME between individ-
uals with SCI and able-bodied (AB) controls.
The purpose of this investigation was to compare BP
and CBFv responses between hypotensive individuals with
SCI and AB controls (with low BP) during cognitive acti-
vation, using two serial subtraction tasks (SSt), one before
(predrug) and one after (postdrug) administration of
MH, L-NAME, and no-drug (ND). A secondary aim was
to determine if changes in BP were correlated with
changes in CBFv from predrug to postdrug following
administration of the antihypotensive agents (MH and L-
NAME). We hypothesized that the BP and CBFv
responses to MH and L-NAME would be augmented in
the SCI compared to the AB group and that changes in
BP would relate to changes in CBFv in those with SCI.
Materials and Methods
Subjects
All subjects (n = 25) were between the ages of 22 and
61 years with no known history of CVD, pulmonary dis-
ease, or diabetes mellitus. Subjects were current nonsmok-
ers for a minimum of 1 year prior to investigation and
were not taking medications known to affect autonomic
cardiovascular function. Subjects were instructed to be
well hydrated and to avoid heavy exertion, caffeine, and
alcoholic beverages for a minimum of 24 h prior to test-
ing. The Institutional Review Board for Human Studies
of the James J. Peters Veterans Affairs Medical Center
granted approval, and informed consent was obtained
prior to study.
Study procedures
Subjects visited the laboratory on three separate occasions
and performed an SSt before and after administration of
L-NAME (1.0 mg/kg), MH (10 mg), or ND. Study visits,
although administered in random order, were not blinded
because L-NAME (Clinalfa, Hauptstrasse 144, 4416 Buben-
dorf, Switzerland) was administered intravenously via an
anticubital catheter, MH (Mylan Pharmaceuticals Inc.
3711 Collins Ferry Road Morgantown, WV 26505) was
administered orally with a glass of water and nothing was
administered on the ND visit. Subjects arrived at the labo-
ratory approximately the same time of day on all three
study visits and remained seated for the duration of test-
ing. Prior to data collection, a 20-min period of quiet rest
was provided in a thermoneutral, dimly lit room while the
subjects were instrumented with ECG electrodes, BP mon-
itors, and a head harness to secure probe placement for
transcranial Doppler (TCD) ultrasound recording of the
left middle cerebral artery (MCA). Immediately following
the quiet rest period, and prior to drug administration,
subjects were asked to perform the SSt (predrug) while
simultaneous beat-to-beat heart rate (HR), BP, and CBF
data were collected. At the completion of the predrug SSt
the drug administration period was initiated – which var-
ied based on the randomly selected visit order and
included: (1) insertion of an intravenous catheter in the
left antecubital vein for the 60-min L-NAME infusion
(20–80 min); (2) oral administration of MH (40 min after
the predrug SSt) or (3) quiet seated rest (ND visit). A sec-
ond SSt (postdrug) was performed 90 min after comple-
tion of the predrug SSt, while simultaneous beat-to-beat
HR, BP, and CBF data were collected.
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Heart rate & blood pressure monitoring
Instrumentation included continuous monitoring of the
inter-beat-interval (IBI: msec) of HR using a standard
electrocardiogram (Ivy Biomedical Systems Inc. 11 Busi-
ness Park Drive Branford, CT 06405-2959). The ECG sig-
nal was recorded from a 3-lead configuration; lead site
preparation was performed according to clinical standards
and electrodes were placed at the distal right and left clav-
icle and in the left lateral 5th intercostal space (V-5).
Beat-to-beat finger BP (mmHg) was continuously moni-
tored at the right middle finger using photoplethysmogra-
phy (Finometer  MIDI Model-2; Finopres Medical
Systems B.V. Amsterdam, the Netherlands). To minimize
interday and intraday variability in the finger BP assess-
ments the photoplethysmographer was calibrated to bra-
chial pressure immediately (30 sec) before each SSt and
the arm was supported horizontal to the level of the heart
on all three study visits. The systemic hemodynamic vari-
ables of interest included IBI, SBP, DBP, and mean arte-
rial pressure (MAP: the primary outcome variable), which
was calculated from finger BP as: (SBP + DBP + DBP)/3.
Cerebral blood flow monitoring
Cerebral blood flow was estimated from blood flow veloc-
ity (FV) assessed at the left MCA using TCD ultrasound
technology (Terumo Cardiovascular Systems 1311 Valen-
cia Avenue Tustin, CA 92780-6447). The left MCA was
isonated because prior work suggests increased activation
with respect to a baseline period during the SSt (Duschek
and Schandry 2006). The TCD probe was operated at a
frequency of 2.0 MHz to visualize the MCA and insona-
tion was through the left temporal window. The MCA
was identified by the target depth (45–55 mm), sound
and direction of flow (i.e., toward the probe), the charac-
teristic spectral waveform, relatively faster FV compared
to other cerebral vessels, and by compression of the com-
mon carotid artery which resulted in an appropriate
reduction in MCA flow velocity. Once the MCA was visu-
alized, a head-harness was used to secure probe placement
for the duration of testing. Data collection output from
the TCD monitor included systolic FV (SFV: cm/sec),
diastolic FV (DFV: cm/sec) and mean FV (MFV: cm/sec);
the primary outcome variable was MFV.
Signal acquisition
The ECG, photoplethysmography, and transcranial Dop-
pler signals were sampled at 500 Hz and were stored on a
hard-drive for subsequent analysis using customized data
analysis programs written with LabVIEW graphical soft-
ware for instrumentation (National Instruments, 11500
North Mopac Expressway Austin, TX 78759-3504).
Cognitive activation
The SSt is an easy to perform, brief assessment of informa-
tion processing speed (Williams et al. 1996). Subjects were
asked to subtract a single-digit number from a three-digit
number in succession for 60 sec. Each SSt began at differ-
ent three-digit starting points and the number being sub-
tracted varied randomly. For instance, subjects may have
been asked to subtract the number 7 from 760 and on the
next task may have been asked to subtract 6 from 801. The
total number of attempts and the number of correct
responses on the predrug SSt were compared between the
SCI and AB groups and the change (from predrug to post-
drug) in total attempts and number of correct responses
was recorded following L-NAME and MH administration.
Hemodynamic data were collected continuously during the
predrug and postdrug SSt and are reported as the average
IBI, BP, and CBFv during the cognitive activation periods.
Data analysis
Data are reported as mean  standard deviation and were
analyzed using a statistical analysis program (IBM SPSS
Statistics 21). Subject characteristic data and performance
on the predrug SSt were compared between the groups
using unpaired t-tests. Factorial analysis of variance
(ANOVA) was used to determine main and interaction
effects for group (SCI, AB) and visit (L-NAME, MH, ND)
for the predrug hemodynamic and cognitive data. To assess
the effects of the drug intervention on the primary out-
come variables of MAP and MFV separate univariate three-
way mixed factorial ANOVA models were constructed to
determine significant interaction and main effects for
group (SCI; AB), visit (L-NAME; MH; ND), and time (pre-
drug; postdrug). Follow-up procedures were employed
depending on the results of the factorial ANOVAs, and the
Huynh–Feldt correction was applied where appropriate.
Simple linear regression models were created for each
group to determine the relationship between the change in
MAP and change in MFV from predrug SSt to postdrug
SSt for the MH and L-NAME visits. Statistical significance
was set at the 0.05 alpha level for all comparisons.
Results
Study subjects
Subjects with SCI (n = 15) were matched for demo-
graphic characteristics to the AB controls (n = 10);
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however, finometer BP recordings were unusable in one
AB participant; therefore results are presented in nine
control subjects. Subject demographic data are presented
(Table 1); height was significantly lower in the AB com-
pared to the SCI group. The study sample was largely
male (75%), 11 were veterans (44%), and the sample was
predominantly Caucasian (52%). Subjects with SCI were
chronically injured (range: 1–42 years), mostly cervical
lesions (80%), and two-thirds were motor complete inju-
ries (AIS A & B).
Serial subtraction task
Although the total number of attempts on all (i.e., 3 per
subject) of the predrug SSt did not differ between the AB
and SCI groups (54.2  27.4 vs. 44.5  27.0, respectively;
P = 0.154) the total number of correct responses on the
predrug SSt was significantly higher in the AB compared
to the SCI group (49.3  28.8 vs. 38.3  27.6, respec-
tively; P = 0.047). However, there was no evidence of
improved performance on the postdrug SSt in either
group, regardless of study visit (data not shown).
Hemodynamics predrug
There were no differences between study visits for the
predrug hemodynamic data; therefore, the average pre-
drug hemodynamic data for the three-study visits are pre-
sented (Table 2). The group main effect was significant
for SBP, MAP, DFV, and MFV, indicating that, regardless
of study visit, BP and CBFv were reduced during the pre-
drug SSt in the SCI compared to the AB group.
Change in systemic hemodynamics
Change in BP from predrug to postdrug is shown for the
two study groups during the three study visits (Figure 1).
The three-way interaction effect was significant for MAP
(F = 4.262; P = 0.020), such that MAP was increased in
the SCI group (Figure 1A) from the predrug SSt to the
postdrug SSt following MH and L-NAME administration,
but was flat following ND and regardless of study drug in
the AB group (Figure 1B). Specifically in the SCI group,
the change in MAP from predrug to postdrug was signifi-
cant following MH (30  26 mmHg, P = 0.011; 95%
CI = 15 to 44 mmHg) and L-NAME (27  22 mmHg,
P = 0.003; 95% CI =15 to 39 mmHg), and the magnitude
of effect was comparable between the two antihypotensive
agents (mean difference MH vs. L-NAME = 3 mmHg;
95% CI = 21 to 16 mmHg). Compared to the ND con-
dition in the SCI group, both drugs increased MAP from
predrug to postdrug (MH vs. ND: mean difference
28 mmHg; 95% CI for difference = 7 to 48 mmHg and
L-NAME vs. ND: mean difference 25 mmHg, 95% CI for
difference = 10 to 41 mmHg). Similar findings were evi-
dent for SBP and DBP (Figure 1C–F).
Change in cerebral hemodynamics
The change from predrug to postdrug in CBFv is pre-
sented for the three study visits in the SCI and AB groups
(Figure 2). Although the three-way interaction effect was
not significant for MFV (Figure 2A, B) the visit by time
interaction was significant. The data indicate an increase
in MFV in both groups from the predrug SSt to the post-
drug SSt following L-NAME (6  8 cm/sec; 95% CI = 3
to 9 cm/sec) and MH (4  7 cm/sec; 95% CI = 1 to
7 cm/sec), with little change following ND (3  3 cm/
sec; 95% CI = 3 to 3 cm/sec). Although follow-up pro-
cedures indicated that the magnitude of change was not
significantly different between L-NAME and MH (95% CI
for difference = 1 to 6 cm/sec), L-NAME increased
MFV from predrug to postdrug relative to the ND condi-
tion (L-NAME vs. ND: mean difference = 6 cm/sec; 95%
Table 1. Subject characteristics
SCI AB
P valuen = 15 n = 9
Age (years) 43  12 36  12 0.181
HT (cm) 176  7 168  9 0.040
WT (kg) 70  10 65  11 0.293
BMI (kg/m2) 22.8  3.6 22.9  2.8 0.911
Female Gender (n) 2 3
Duration (years) 13  12
Level of SCI C3-T4
Complete AIS A 5 (33%)
HT, height; cm, centimeters; WT, weight; kg, kilograms; BMI,
body mass index.
Table 2. Predrug hemodynamics
SCI AB P value
IBI (msec) 790  160 767  126 0.717
SBP (mmHg) 92  22 119  30 0.009
MAP (mmHg) 68  19 82  15 0.021
DBP (mmHg) 54  17 63  13 0.075
SFV (cm/sec) 65  14 80  23 0.053
MFV (cm/sec) 37  10 52  15 0.005
DFV (cm/sec) 23  10 33  12 0.023
IBI, interbeat interval; SBP, systolic blood pressure; DBP, diastolic
blood pressure; MAP, mean arterial pressure; SFV, systolic flow
velocity; MFV, mean flow velocity; DFV, diastolic flow velocity.
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Figure 1. Change from predrug to postdrug following L-NAME (open triangles), MH (closed squares) and ND (open circles) for MAP (top
































































































Figure 2. Change from predrug to postdrug following L-NAME (open triangles), MH (closed squares) and ND (open circles) for MFV (top
panels), SFV (middle panels), and DFV (bottom panels) in the SCI (A, C, E) and AB (B, D, F) groups.
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CI for difference = 2 to 11 cm/sec), whereas MH did not
quite reach significance (MH vs. ND: mean differ-
ence = 4 cm/sec; 95% CI for difference = 0.2 to 8 cm/
sec). Increase in MFV during the postdrug SSt was largely
attributable to changes in DFV (Figure 2E, F), because,
regardless of study visit there were no significant effects
for SFV (Figures 2C, D).
Relationship between MAP & MFV
The relationship between change in MAP (mmHg) and
change MFV (cm/sec) is depicted for the SCI group
(Figure 3). Change in MFV was significantly associated
with change in MAP following administration of L-
NAME (r = 0.57, slope = 0.26 cm 9 sec1 9 mmHg1;
P = 0.03) and MH (r = 0.62; slope = 0.18 cm 9 sec1
9 mmHg1; P = 0.01). For the L-NAME analyses, one
outlier was identified using both Mahalanobis distance
(criterion = distance > the mean distance +3 times the
standard deviation of the Mahalanobis distance) as well
as having a Cook’s distance = 3.72 (reflecting a data
point with undue influence on the regression calcula-
tions). The outlying data point is indicated in Figure 3
(*) and the regression line was generated without this
outlier, using an n = 14.
Discussion
The primary aim of this investigation was to determine
BP and CBFv responses to MH and L-NAME in hypoten-
sive individuals with SCI compared to AB controls during
cognitive activation. The data suggest that these antihy-
potensive agents, at the doses tested, increased MAP in
the SCI group but had no effect on MAP in the AB
group. However, the effect of these antihypotensive agents
on CBFv was mixed. Regardless of group affiliation MFV
was increased following L-NAME administration, whereas
MFV was increased following MH administration in the
SCI group alone. A secondary aim was to determine if
there was an association between the change in BP and
the change in CBFv from the predrug SSt to the postdrug
SSt. As anticipated, change in MAP correlated with
change in MFV following administration of either
L-NAME or MH in the SCI group.
Predrug hemodynamics: cognitive function
Blood pressure and cerebral blood flow velocity were uni-
formly lower in the hypotensive individuals with SCI
compared to AB controls during the predrug SSt and
subjects with SCI responded with fewer correct answers
than the AB controls. However, by study design, all sub-
jects with SCI were hypotensive, and therefore we cannot
determine if the low BP contributed to the poor perfor-
mance on the predrug SST or if the SCI per se was con-
tributory. That said, our previous findings suggest that
hypotensive individuals with SCI perform more poorly
than normotensive individuals with SCI on cognitive tests
assessing memory (California Verbal Learning Test) and
attention processing (Oral Trails A) (Jegede et al. 2010),
and we have shown that individuals with SCI, regardless
of the level of lesion (C4-T10), do not appropriately
adjust CBFv during cognitive testing (Stroop test), which
related to poor test performance compared to AB controls
(Wecht et al. 2012). The SSt assesses complex attention
and speed of information processing (Williams et al.
1996), and although diabetics scored more poorly than
nondiabetics, scores on the SSt did not differ between
individuals with and without hypertension (Hawkins
et al. 2011). Therefore, blood pressure may not contribute
to performance on the SSt, which could have accounted
for the lack of improvement in scores following BP eleva-
tion in our subjects with SCI. Future studies should
investigate the effects of BP elevation on memory in
hypotensive individuals with SCI.
Hypertensive effect: SCI versus AB
These antihypotensive agents increased seated BP from
the predrug SSt to the postdrug SSt in subjects with SCI,
but had no effect in AB controls. Individuals with high
level SCI (T4 and above), have some degree of decentral-
ized peripheral sympathetic vasomotor control, which
results in frankly low levels of resting plasma nore-























Figure 3. Relationship between change in MAP and change in
MFV from predrug to postdrug during the SSt following MH (closed
circles) and LN (open squares) in the SCI group. The slope of this
relationship was significant for MH (r2 = 0.39; P < 0.01) and LN
(r2 = 0.33; P < 0.05).
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It is believed that the prolific hypotension reported in
individuals with high level SCI is a consequence of low
plasma NE (Claydon and Krassioukov 2006), and that the
responsiveness to antihypotensive therapy reflects inade-
quate baroreceptor buffering of BP (Wecht et al. 2008).
In contrast, we believe that the healthy AB controls were
able to buffer the rise in BP following administration of
these antihypotensive agents by withdrawing tonic periph-
eral sympathetic vasomotor control (i.e., NE), as we pre-
viously demonstrated in response to L-NAME infusion
(Wecht et al. 2008). Moreover, the increase in BP was
comparable following administration of L-NAME (NOS
inhibitor) and MH (alpha-agonist) in the SCI group, sug-
gesting that the BP response was independent of the
mechanism responsible for the hypertensive response.
Pressure flow relationship: autonomic
impairment
The statistically significant relationship between change in
MAP and change in MFV in the SCI group suggests that
decentralized sympathetic cardiovascular control may alter
the systemic pressure-cerebral flow relationship. There is
evidence of a passive relationship between systemic BP and
CBF in several models of impaired peripheral sympathetic
vascular control. Using positron emission tomography in
individuals with autonomic failure secondary to Shy-Dra-
ger syndrome a 19% increase in BP was associated with a
22% increase in CBFv (Ogawa et al. 1998) and superior
cervical sympathetic nerve stimulation caused an increase
in MCA flow velocity, which was directly related to an
increase in systemic BP in three patients undergoing sur-
gery for palmar hyperhidrosis.(Wahlgren et al. 1992)
Moreover, pharmacologic manipulation of adrenergic sym-
pathetic vascular control during rapid changes in BP sec-
ondary to the Valsalva maneuver (Zhang et al. 2004a) and
thigh cuff deflation (Ogoh et al. 2008) demonstrate alter-
ation in CBFv that differed significantly from a control
condition. This evidence suggests that the autonomic ner-
vous system may play a role in maintaining the relationship
between systemic BP and CBFv and when autonomic regu-
latory control is altered, the pressure-flow relationship may
be impaired. While sympathetic adrenergic impairment
may be a pathophysiological adaptation during rapid
changes in BP, this altered pressure-flow relationship may
serve to improve CBFv following antihypotensive treatment
in the SCI population.
Pressure flow relationship: L-NAME versus
MH
There is conflicting evidence describing the effects of
increase in BP on CBFv following administration of
alpha-agonists or NOS inhibitors. Increased MFV has
been reported concurrent with BP elevation following
administration of MH in models of essential hypotension,
(Duschek et al. 2007a, b) in hemodialysis patients with
orthostatic hypotension, (Fujisaki et al. 2007) and, follow-
ing administration of L-NAME a transient increase in
CBF was reported in rats (Koskinen and Koch 2003). In
addition, we previously reported a significant association
between the change in MAP and MFV from supine to
45° head-up tilt in hypotensive individuals with SCI
(Wecht et al. 2011). In contrast, Phillips et al., reported
significant increases in seated (Phillips et al. 2014b) and
supine (Phillips et al. 2014a) MAP following administra-
tion of MH (10 mg); with no effect on MCA CBFv in ten
individual with SCI (C4-T5). In addition, Zhang et al.
reported comparable increases in MAP following adminis-
tration of the NOS inhibitor L-NMMA (NG-mono-
methyl-L-arginine) and an a1-agonist (phenylephrine) in
healthy AB controls, but neither agent increased CBFv
(Zhang et al. 2004b).
While neither the alpha agonist nor the NOS inhibitor
significantly raised MAP in the AB controls, L-NAME
appeared to increase MFV. This finding is in contrast to
prior work demonstrating that although supine MAP was
increased by 13% following systemic administration L-
NMMA CBFv remained unchanged (Zhang et al. 2004b).
We speculate that the MFV response to L-NAME reflects
suppressed tonic inhibition of extra-cranial sympathetic
regulation of CBF by nitric oxide, independent of BP
(Willie et al. 2014). An alternative explanation is that
NOS inhibition may have reduced the diameter of the
MCA (Stewart et al. 2013), which artificially increased
TCD recording of flow velocity, but may not be indicative
of a true increase in CBF.
Clinical side-note
It should be noted that the MAP and MFV responses to
the study drugs varied among the individual participants
with SCI. Six subjects with SCI responded with an equiv-
alent rise in MAP following L-NAME and MH, five sub-
jects responded better to L-NAME and four responded
better to MH. While seven subjects with SCI had a simi-
lar increase in MFV following L-NAME and MH admin-
istration, four subjects responded better to L-NAME, and
two subjects responded better to MH; two subjects did
not respond with an increase in MFV following adminis-
tration of either L-NAME or MH. Furthermore, it must
be appreciated that although the relationship between
MAP and MFV in the SCI group was significant, change
MAP accounted for only about 1/3rd of the variance in
the change in MFV, which probably relates to the
variability in individual response to these different
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antihypotensive agents. Taken together, these data suggest
that, analogous to treatment of hypertension, individual
responses to antihypotensive therapy vary and therefore
development of a pharmacological armamentarium for
the safe and effective treatment of hypotension in the SCI
population is important.
Limitations
Doppler ultrasound of the MCA assumes that vessel
diameter remains constant throughout testing; however,
we cannot account for the potential differential influence
of these antihypotensive agents on the diameter of the
MCA. In fact, there is recent evidence suggesting that
administration of a nitric oxide donor (sodium nitroprus-
side) increases the diameter of the MCA (Stewart et al.
2013); therefore, systemic administration of L-NAME,
may have influenced MCA diameter thereby contributing
to changes in CBF independent of changes in flow veloc-
ity or BP. We recently reported poor day-to-day repro-
ducibility of finger BP assessments in the SCI and AB
populations; however, we were unable to collect brachial
BP during the 60 sec SSt, due to the short duration of
the test and distraction to subjects; therefore, the BP data
should be interpreted with caution. Conclusions regarding
the ability to improve cognitive performance by increas-
ing BP or CBFv are still speculative and cannot be
confirmed with these data. Finally, the clinical utility of
L-NAME is questionable because NOS inhibition is not
presently available as an FDA approved agent for treat-
ment of hypotension.
Conclusion
Both L-NAME and MH, at the doses tested, relieved the
hypotension in subjects with SCI and attenuated group
differences in CBFv during cognitive activation. More-
over, the findings suggest that increase in MAP was asso-
ciated with increase in MFV in subjects with SCI. We
believe that optimal BP control should involve ascertain-
ing the effects of antihypotensive medications on CBF
rather than treating solely to “normalize” BP. Additional
data are needed to determine the dose and length of time
required to normalize CBF, and improve cognitive perfor-
mance following BP elevation and for the development a
clinical armamentarium for the safe and effective treat-
ment of asymptomatic hypotension in the SCI popula-
tion.
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